Merus NV

MRUSNASDAQ NMS - GLOBAL MARKET

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 260 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.

Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Merus NV.